An open-label phase II study enrolled 267 patients treated with T-DXd (5.4 mg/kg once every 3 weeks), demonstrating its efficacy in HER2-expressing solid tumors across seven tumor types: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and others (23). This evidence concerns the gene ERBB2 and neoplasm.